Clinical trials
Terminated Bacteremia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 2 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 30 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 3 |
| Pfizer | 2 |
| AbbVie | 1 |
| Assistance Publique - Hôpitaux de Paris | 1 |
| Beth Israel Medical Center | 1 |
| CAMC Health System | 1 |
| Charite University, Berlin, Germany | 1 |
| Cumberland Pharmaceuticals | 1 |
| East Carolina University | 1 |
| Henry Ford Health System | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bacteremia | 30 |
| Staphylococcal Infections | 6 |
| Endocarditis | 5 |
| Gram-Positive Bacterial Infections | 5 |
| Sepsis | 5 |
| Pneumonia | 4 |
| Arthritis, Infectious | 2 |
| Bacterial Infections | 2 |
| Catheter-Related Infections | 2 |
| Endocarditis, Bacterial | 2 |
Trials
Showing 76 to 30 of 30. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.